1. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference
- Author
-
Giuseppe Boriani, Andreas Goette, Isabelle C. Van Gelder, Gerhard Steinbeck, Ursula Ravens, Carina Blomström-Lundqvist, Stephan Willems, Luis Mont, Paulus Kirchhof, Andreas Clemens, Nilo B. Cater, Robert Hatala, Axel Brandes, A. John Camm, Stefan Kääb, Jeroen J. Bax, Guenter Breithardt, Leif Friberg, Maria Borentain, Karl Wegscheider, Juergen Polifka, Dieter Paar, Michael Nabauer, Hein Heidbuchel, Michele Massimo Gulizia, Trudie Lobban, Ulrich Schotten, Josef Kautzner, Elaine M. Hylek, John M. Morgan, Wim Stegink, Lukas Szumowski, Paul Dorian, Jenny Horwood, Angelika Leute, Ralf Meyer, Alphons Vincent, Dobromir Dobrev, Deirdre A. Lane, Stefanie Breitenstein, Hans-Christoph Diener, Laurent M. Haegeli, Nils Edvardsson, Michael Oeff, Michael D. Ezekowitz, Lukas Kappenberger, Sergio Dubner, Gregory Y.H. Lip, Christoph Baertels, Panos E. Vardas, Martina Brueckmann, Maria Aunes-Jansson, Felix Muenzel, Maureen V Walter, Jay Millerhagen, Ludger Rosin, Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, Boriani G, Brandes A, Ezekowitz M, Diener H, Haegeli L, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Aunes-Jansson M, Blomstrom-Lundqvist C, Borentain M, Breitenstein S, Brueckmann M, Cater N, Clemens A, Dobrev D, Dubner S, Edvardsson NG, Friberg L, Goette A, Gulizia M, Hatala R, Horwood J, Szumowski L, Kappenberger L, Kautzner J, Leute A, Lobban T, Meyer R, Millerhagen J, Morgan J, Muenzel F, Nabauer M, Baertels C, Oeff M, Paar D, Polifka J, Ravens U, Rosin L, Stegink W, Steinbeck G, Vardas P, Vincent A, Walter M, Breithardt G, Camm AJ., Fysiologie, and RS: CARIM School for Cardiovascular Diseases
- Subjects
Male ,Heart disease ,Medizin ,antithrombotic therapy ,Management of atrial fibrillation ,outcomes ,GLOMERULAR-FILTRATION-RATE ,ATRIAL FIBRILLATION ,BIOLOGICAL MARKERS ,TREATMENT OUTCOME ,Antithrombotic ,Atrial Fibrillation ,RADIOFREQUENCY CATHETER ABLATION ,risk factors ,rhythm control ,early therapy ,CARDIOVASCULAR INTERVENTIONS EAPCI ,Atrial fibrillation ,C-REACTIVE PROTEIN ,VENTRICULAR SYSTOLIC DYSFUNCTION ,Treatment Outcome ,Female ,Cardiology and Cardiovascular Medicine ,Anti-Arrhythmia Agents ,management ,medicine.medical_specialty ,Long QT syndrome ,MEDLINE ,Reviews ,LONG-QT SYNDROME ,Early Therapy ,CARDIOLOGY WORKING GROUP ,CEREBRAL AMYLOID ANGIOPATHY ,Fibrinolytic Agents ,Physiology (medical) ,medicine ,Animals ,Humans ,STERILE PERICARDITIS MODEL ,Intensive care medicine ,LOBAR INTRACEREBRAL HEMORRHAGE ,rate control ,business.industry ,medicine.disease ,Rats ,business ,Risk Reduction Behavior ,Fibrinolytic agent ,Biomarkers - Abstract
While management of atrial fibrillation (AF) patients is improved by guideline-conform application of anticoagulant therapy, rate control, rhythm control, and therapy of accompanying heart disease, the morbidity and mortality associated with AF remain unacceptably high. This paper describes the proceedings of the 3rd Atrial Fibrillation NETwork (AFNET)/European Heart Rhythm Association (EHRA) consensus conference that convened over 60 scientists and representatives from industry to jointly discuss emerging therapeutic and diagnostic improvements to achieve better management of AF patients. The paper covers four chapters: (i) risk factors and risk markers for AF; (ii) pathophysiological classification of AF; (iii) relevance of monitored AF duration for AF-related outcomes; and (iv) perspectives and needs for implementing better antithrombotic therapy. Relevant published literature for each section is covered, and suggestions for the improvement of management in each area are put forward. Combined, the propositions formulate a perspective to implement comprehensive management in AF.
- Published
- 2012